Pharmaron Beijing Co., Ltd. (03759.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	15.1B	14.1B	12.3B	11.5B	10.3B
Cost of Revenue	10.1B	9.2B	8.1B	7.4B	6.5B
Gross Profit	5.1B	4.9B	4.2B	4.1B	3.8B
Operating Expenses
R&D Expense	608.2M	576.0M	469.3M	448.3M	282.3M
SG&A Expense	959.8M	788.7M	720.5M	1.9B	969.5M
General & Admin Expense	1.4B	736.5M	676.1M	1.6B	739.4M
Selling & Marketing Expense	202.3M	52.2M	44.4M	252.8M	230.1M
Other Expenses	1.4B	1.6B	908.9M	(66.9M)	766.0M
Total Operating Expenses	3.0B	3.0B	2.1B	2.3B	2.0B
Cost and Expenses	13.0B	12.2B	10.2B	9.7B	8.5B
Operating Income (EBIT)	2.1B	1.9B	2.1B	1.8B	1.7B
Non-Operating
Interest Income	57.0M	39.4M	73.6M	29.9M	35.2M
Interest Expense	197.9M	192.8M	243.7M	182.2M	167.3M
Net Interest Income	(140.9M)	(153.4M)	(174.3M)	(152.3M)	(134.6M)
Other Non-Op Income/Expense	(79.8M)	(15.8M)	(13.2M)	(10.0M)	(23.5M)
Non-Operating Income (excl Interest)	(119.9M)	(177.0M)	(230.5M)	(172.2M)	(143.8M)
EBT (Pre-Tax Income)	2.0B	1.9B	2.1B	1.8B	1.7B
Income Tax Expense	410.4M	357.5M	377.1M	256.1M	314.3M
Bottom Line
Net Income	1.7B	1.7B	1.8B	1.6B	1.4B
Earnings from Cont. Ops	1.6B	1.6B	1.7B	1.6B	1.4B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	1.7B	1.7B	1.8B	1.6B	1.4B
Per Share
Basic EPS	HK$0.96	HK$0.94	HK$1.01	HK$1.00	HK$0.90
Diluted EPS	HK$0.96	HK$0.94	HK$1.01	HK$1.00	HK$0.90
Revenue Per Share	HK$8.21	HK$8.00	HK$6.87	HK$6.51	HK$5.79
Shares
Basic Shares Outstanding	1.8B	1.8B	1.8B	1.8B	1.8B
Diluted Shares Outstanding	1.8B	1.8B	1.8B	1.8B	1.8B
Profitability Metrics
EBITDA	2.6B	3.3B	3.4B	2.9B	2.5B
D&A	359.7M	1.2B	1.0B	927.2M	696.2M
EBIT	2.2B	2.1B	2.3B	2.0B	1.8B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026